By Cristina Carapezza
Rosen Wins TV Headrest Patent Suit
The Federal Circuit upheld the district court’s decision that Rosen Entertainment Systems LP did not infringe a TMI Products Inc. patent for video devices that can be installed into the back of a car’s headrest. TMI contended that the district court incorrectly interpreted the claim term “to permit selective access.” However, a three-judge appellate panel found that U.S. District Judge R. Gary Klausner correctly construed the disputed language of claim 1 that constituted the basis for his decision. Thus, the Federal Circuit affirmed the decision of the court to grant Rosen’s motion for summary judgment of noninfringement.
Federal Circuit Allows for Declaratory Judgment of Noninfringement for Disclaimed Patent
The Federal Circuit reversed the district court’s dismissal of Apotex Inc.’s suit seeking a declaratory judgment on noninfringement of Daiichi Sankyo Inc.’s patent for olmesartan medoxomil, which Daiichi markets as Benicar® for the treatment of hypertension. Apotex seeks to manufacture and sell a generic verison of Benicar®. Although Apotex cannot infringe the patent because Daiichi disclaimed it, a declaratory judgment on noninfringement allows Apotex to obtain marketing approval from the United States Food and Drug Administration and to enter the market sooner than would be possible otherwise. The district court granted Daiichi’s motion to dismiss for a lack of case or controversy. However, the Federal Circuit reversed, in part, because “Apotex has a concrete, potentially high-value stake in obtaining the judgment it seeks; and Daiichi has a concrete, potentially high-value stake in denying Apotex that judgment and thereby delaying Apotex’s market entry.” Thus, the Federal Circuit found that a substantial controversy existed to warrant the issuance of a declaratory judgment.
Federal Circuit Prohibits Third Party Challenges to Patent Application Revivals Under the APA
The Federal Circuit rejected Excela Pharma Sciences LLC’s appeal of a ruling by the U.S. Patent and Trademark Office (USPTO) denying Exela’s challenge of the USPTO’s decision to revive a patent application. The patent at issue is for Ofirmev, an injectable pain reliever, owned by SCR Pharmatop and sublicensed to Cadence Pharmaceuticals Inc. The district court dismissed Exela’s complaint for not meeting the statute of limitations for claims filed against the U.S. Regardless of whether the challenge was time-barred, the Federal Circuit ruled that a third party to a patent cannot use the Administrative Procedure Act to seek judicial review of a USPTO decision to revive a patent application that was abandoned because of late filings.